{"PubmedBookArticle": [], "PubmedArticle": [{"MedlineCitation": {"KeywordList": [["MDM2", "Natural products", "Oncogene", "Tumor suppressor", "p53"]], "SpaceFlightMission": [], "InvestigatorList": [], "OtherAbstract": [], "OtherID": [], "CitationSubset": [], "GeneralNote": [], "PMID": "30320185", "DateRevised": {"Year": "2020", "Month": "09", "Day": "30"}, "Article": {"ArticleDate": [{"Year": "2018", "Month": "07", "Day": "20"}], "Language": ["eng"], "ELocationID": ["10.1016/j.gendis.2018.07.002"], "Journal": {"ISSN": "2352-3042", "JournalIssue": {"Volume": "5", "Issue": "3", "PubDate": {"Year": "2018", "Month": "Sep"}}, "Title": "Genes & diseases", "ISOAbbreviation": "Genes Dis"}, "ArticleTitle": "Natural products targeting the p53-MDM2 pathway and mutant p53: Recent advances and implications in cancer medicine.", "Pagination": {"StartPage": "204", "EndPage": "219", "MedlinePgn": "204-219"}, "Abstract": {"AbstractText": ["The p53 tumor suppressor plays a major role in controlling the initiation and development of cancer by regulating cell cycle arrest, apoptosis, senescence, and DNA repair. The MDM2 oncogene is a major negative regulator of p53 that inhibits the activity of p53 and reduces its protein stability. MDM2, p53, and the p53-MDM2 pathway represent well-documented targets for preventing and/or treating cancer. Natural products, especially those from medicinal and food plants, are a rich source for the discovery and development of novel therapeutic and preventive agents against human cancers. Many natural product-derived MDM2 inhibitors have shown potent efficacy against various human cancers. In contrast to synthetic small-molecule MDM2 inhibitors, the majority of which have been designed to inhibit MDM2-p53 binding and activate p53, many natural product inhibitors directly decrease MDM2 expression and/or MDM2 stability, exerting their anticancer activity in both p53-dependent and p53-independent manners. More recently, several natural products have been reported to target mutant p53 in cancer. Therefore, identification of natural products targeting MDM2, mutant p53, and the p53-MDM2 pathway can provide a promising strategy for the development of novel cancer chemopreventive and chemotherapeutic agents. In this review, we focus our discussion on the recent advances in the discovery and development of anticancer natural products that target the p53-MDM2 pathway, emphasizing several emerging issues, such as the efficacy, mechanism of action, and specificity of these natural products."]}, "AuthorList": [{"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of Pharmacological and Pharmaceutical Sciences, College of Pharmacy, University of Houston, Houston, TX, 77204, USA."}], "LastName": "Qin", "ForeName": "Jiang-Jiang", "Initials": "JJ"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of Pharmacological and Pharmaceutical Sciences, College of Pharmacy, University of Houston, Houston, TX, 77204, USA."}], "LastName": "Li", "ForeName": "Xin", "Initials": "X"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Center for Drug Discovery, University of Houston, Houston, TX, 77204, USA."}], "LastName": "Hunt", "ForeName": "Courtney", "Initials": "C"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of Pharmacological and Pharmaceutical Sciences, College of Pharmacy, University of Houston, Houston, TX, 77204, USA."}, {"Identifier": [], "Affiliation": "Center for Drug Discovery, University of Houston, Houston, TX, 77204, USA."}], "LastName": "Wang", "ForeName": "Wei", "Initials": "W"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "School of Public Health, Shanghai Jiao Tong University School of Medicine, Shanghai, 200025, China."}], "LastName": "Wang", "ForeName": "Hui", "Initials": "H"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of Pharmacological and Pharmaceutical Sciences, College of Pharmacy, University of Houston, Houston, TX, 77204, USA."}, {"Identifier": [], "Affiliation": "Center for Drug Discovery, University of Houston, Houston, TX, 77204, USA."}], "LastName": "Zhang", "ForeName": "Ruiwen", "Initials": "R"}], "GrantList": [{"GrantID": "R01 CA186662", "Acronym": "CA", "Agency": "NCI NIH HHS", "Country": "United States"}, {"GrantID": "R01 CA214019", "Acronym": "CA", "Agency": "NCI NIH HHS", "Country": "United States"}], "PublicationTypeList": ["Journal Article", "Review"]}, "MedlineJournalInfo": {"Country": "Netherlands", "MedlineTA": "Genes Dis", "NlmUniqueID": "101635967", "ISSNLinking": "2352-3042"}}, "PubmedData": {"ReferenceList": [{"ReferenceList": [], "Reference": [{"Citation": "Lee E.Y., Muller W.J. Oncogenes and tumor suppressor genes. Cold Spring Harb Perspect Biol. 2010;2(10):a003236.", "ArticleIdList": ["PMC2944361", "20719876"]}, {"Citation": "Zhu K., Liu Q., Zhou Y. Oncogenes and tumor suppressor genes: comparative genomics and network perspectives. BMC Genom. 2015;16(suppl 7):S8.", "ArticleIdList": ["PMC4474543", "26099335"]}, {"Citation": "Berger T., Saunders M.E., Mak T.W. Beyond the oncogene revolution: four new ways to combat cancer. Cold Spring Harb Symp Quant Biol. 2016;81:85\u201392.", "ArticleIdList": ["28057846"]}, {"Citation": "Sabapathy K. The contrived mutant p53 oncogene - beyond loss of functions. Front Oncol. 2015;5:276.", "ArticleIdList": ["PMC4674554", "26697411"]}, {"Citation": "Fritsche M.K., Knopf A. The tumor suppressor p53 in mucosal melanoma of the head and neck. Genes. 2017;8(12):384.", "ArticleIdList": ["PMC5748702", "29236030"]}, {"Citation": "Velez-Cruz R., Johnson D.G. The retinoblastoma (RB) tumor suppressor: pushing back against genome instability on multiple fronts. Int J Mol Sci. 2017;18(8):1776.", "ArticleIdList": ["PMC5578165", "28812991"]}, {"Citation": "Bishayee A., Sethi G. Bioactive natural products in cancer prevention and therapy: progress and promise. Semin Cancer Biol. 2016;40\u201341:1\u20133.", "ArticleIdList": ["27565447"]}, {"Citation": "Qin J., Wang W., Zhang R. Novel natural product therapeutics targeting both inflammation and cancer. Chin J Nat Med. 2017;15(6):401\u2013416.", "ArticleIdList": ["PMC6663108", "28629530"]}, {"Citation": "Nguyen D., Liao W., Zeng S.X. Reviving the guardian of the genome: small molecule activators of p53. Pharmacol Ther. 2017;178:92\u2013108.", "ArticleIdList": ["PMC5601031", "28351719"]}, {"Citation": "Nag S., Qin J., Srivenugopal K.S. The MDM2-p53 pathway revisited. J Biomed Res. 2013;27(4):254\u2013271.", "ArticleIdList": ["PMC3721034", "23885265"]}, {"Citation": "Qin J.J., Nag S., Voruganti S. Natural product MDM2 inhibitors: anticancer activity and mechanisms of action. Curr Med Chem. 2012;19(33):5705\u20135725.", "ArticleIdList": ["PMC6690201", "22830335"]}, {"Citation": "Ware P.L., Snow A.N., Gvalani M. MDM2 copy numbers in well-differentiated and dedifferentiated liposarcoma: characterizing progression to high-grade tumors. Am J Clin Pathol. 2014;141(3):334\u2013341.", "ArticleIdList": ["24515760"]}, {"Citation": "Momand J., Jung D., Wilczynski S. The MDM2 gene amplification database. Nucleic Acids Res. 1998;26(15):3453\u20133459.", "ArticleIdList": ["PMC147746", "9671804"]}, {"Citation": "Onel K., Cordon-Cardo C. MDM2 and prognosis. Mol Cancer Res. 2004;2(1):1\u20138.", "ArticleIdList": ["14757840"]}, {"Citation": "Yu Q., Li Y., Mu K. Amplification of Mdmx and overexpression of MDM2 contribute to mammary carcinogenesis by substituting for p53 mutations. Diagn Pathol. 2014;9:71.", "ArticleIdList": ["PMC3986947", "24667108"]}, {"Citation": "Nag S., Zhang X., Srivenugopal K.S. Targeting MDM2-p53 interaction for cancer therapy: are we there yet? Curr Med Chem. 2014;21(5):553\u2013574.", "ArticleIdList": ["PMC6690199", "24180275"]}, {"Citation": "Karni-Schmidt O., Lokshin M., Prives C. The roles of MDM2 and MDMX in cancer. Annu Rev Pathol. 2016;11:617\u2013644.", "ArticleIdList": ["PMC6028239", "27022975"]}, {"Citation": "Barak Y., Gottlieb E., Juven-Gershon T. Regulation of mdm2 expression by p53: alternative promoters produce transcripts with nonidentical translation potential. Genes Dev. 1994;8(15):1739\u20131749.", "ArticleIdList": ["7958853"]}, {"Citation": "Oliner J.D., Pietenpol J.A., Thiagalingam S. Oncoprotein MDM2 conceals the activation domain of tumour suppressor p53. Nature. 1993;362(6423):857\u2013860.", "ArticleIdList": ["8479525"]}, {"Citation": "Haupt Y., Maya R., Kazaz A. Mdm2 promotes the rapid degradation of p53. Nature. 1997;387(6630):296\u2013299.", "ArticleIdList": ["9153395"]}, {"Citation": "Kubbutat M.H., Jones S.N., Vousden K.H. Regulation of p53 stability by Mdm2. Nature. 1997;387(6630):299\u2013303.", "ArticleIdList": ["9153396"]}, {"Citation": "Kulikov R., Letienne J., Kaur M. Mdm2 facilitates the association of p53 with the proteasome. Proc Natl Acad Sci U S A. 2010;107(22):10038\u201310043.", "ArticleIdList": ["PMC2890462", "20479273"]}, {"Citation": "Carter S., Bischof O., Dejean A. C-terminal modifications regulate MDM2 dissociation and nuclear export of p53. Nat Cell Biol. 2007;9(4):428\u2013435.", "ArticleIdList": ["17369817"]}, {"Citation": "Geyer R.K., Yu Z.K., Maki C.G. The MDM2 RING-finger domain is required to promote p53 nuclear export. Nat Cell Biol. 2000;2(9):569\u2013573.", "ArticleIdList": ["10980696"]}, {"Citation": "Qin J.J., Wang W., Zhang R. Experimental therapy of advanced breast cancer: targeting NFAT1-MDM2-p53 pathway. Prog Mol Biol Transl Sci. 2017;151:195\u2013216.", "ArticleIdList": ["PMC6663080", "29096894"]}, {"Citation": "Bouska A., Eischen C.M. Murine double minute 2: p53-independent roads lead to genome instability or death. Trends Biochem Sci. 2009;34(6):279\u2013286.", "ArticleIdList": ["19447627"]}, {"Citation": "Bohlman S., Manfredi J.J. p53-independent effects of Mdm2. Subcell Biochem. 2014;85:235\u2013246.", "ArticleIdList": ["PMC5507576", "25201198"]}, {"Citation": "Rayburn E.R., Ezell S.J., Zhang R. Recent advances in validating MDM2 as a cancer target. Anticancer Agents Med Chem. 2009;9(8):882\u2013903.", "ArticleIdList": ["PMC6728151", "19538162"]}, {"Citation": "Zhang Z., Wang H., Li M. Novel MDM2 p53-independent functions identified through RNA silencing technologies. Ann N Y Acad Sci. 2005;1058:205\u2013214.", "ArticleIdList": ["16394138"]}, {"Citation": "Turner N., Moretti E., Siclari O. Targeting triple negative breast cancer: is p53 the answer? Cancer Treat Rev. 2013;39(5):541\u2013550.", "ArticleIdList": ["23321033"]}, {"Citation": "Haupt S., Vijayakumaran R., Panimaya J. The role of MDM2 and MDM4 in breast cancer development and prevention. J Mol Cell Biol. 2017;9(1):53\u201361.", "ArticleIdList": ["PMC5439375", "28096293"]}, {"Citation": "Zhang Z., Zhang R. p53-independent activities of MDM2 and their relevance to cancer therapy. Curr Cancer Drug Targets. 2005;5(1):9\u201320.", "ArticleIdList": ["15720185"]}, {"Citation": "Zhang Z., Li M., Wang H. Antisense therapy targeting MDM2 oncogene in prostate cancer: effects on proliferation, apoptosis, multiple gene expression, and chemotherapy. Proc Natl Acad Sci U S A. 2003;100(20):11636\u201311641.", "ArticleIdList": ["PMC208810", "13130078"]}, {"Citation": "Zhang Z., Wang H., Li M. MDM2 is a negative regulator of p21WAF1/CIP1, independent of p53. J Biol Chem. 2004;279(16):16000\u201316006.", "ArticleIdList": ["14761977"]}, {"Citation": "Jin Y., Lee H., Zeng S.X. MDM2 promotes p21waf1/cip1 proteasomal turnover independently of ubiquitylation. EMBO J. 2003;22(23):6365\u20136377.", "ArticleIdList": ["PMC291841", "14633995"]}, {"Citation": "Xu H., Zhang Z., Li M. MDM2 promotes proteasomal degradation of p21Waf1 via a conformation change. J Biol Chem. 2010;285(24):18407\u201318414.", "ArticleIdList": ["PMC2881766", "20308078"]}, {"Citation": "Zhang Z., Wang H., Li M. Stabilization of E2F1 protein by MDM2 through the E2F1 ubiquitination pathway. Oncogene. 2005;24(48):7238\u20137247.", "ArticleIdList": ["16170383"]}, {"Citation": "Ohtani K., DeGregori J., Nevins J.R. Regulation of the cyclin E gene by transcription factor E2F1. Proc Natl Acad Sci U S A. 1995;92(26):12146\u201312150.", "ArticleIdList": ["PMC40313", "8618861"]}, {"Citation": "Uchida C., Miwa S., Kitagawa K. Enhanced Mdm2 activity inhibits pRB function via ubiquitin-dependent degradation. EMBO J. 2005;24(1):160\u2013169.", "ArticleIdList": ["PMC544902", "15577944"]}, {"Citation": "Sdek P., Ying H., Chang D.L. MDM2 promotes proteasome-dependent ubiquitin-independent degradation of retinoblastoma protein. Mol Cell. 2005;20(5):699\u2013708.", "ArticleIdList": ["16337594"]}, {"Citation": "Yang J.Y., Zong C.S., Xia W. ERK promotes tumorigenesis by inhibiting FOXO3a via MDM2-mediated degradation. Nat Cell Biol. 2008;10(2):138\u2013148.", "ArticleIdList": ["PMC2376808", "18204439"]}, {"Citation": "Brenkman A.B., de Keizer P.L., van den Broek N.J. Mdm2 induces mono-ubiquitination of FOXO4. PLoS One. 2008;3(7):e2819.", "ArticleIdList": ["PMC2475507", "18665269"]}, {"Citation": "Yang J.Y., Zong C.S., Xia W. MDM2 promotes cell motility and invasiveness by regulating E-cadherin degradation. Mol Cell Biol. 2006;26(19):7269\u20137282.", "ArticleIdList": ["PMC1592879", "16980628"]}, {"Citation": "Li M., Zhang Z., Hill D.L. Genistein, a dietary isoflavone, down-regulates the MDM2 oncogene at both transcriptional and posttranslational levels. Cancer Res. 2005;65(18):8200\u20138208.", "ArticleIdList": ["16166295"]}, {"Citation": "Fang J., Xia C., Cao Z. Apigenin inhibits VEGF and HIF-1 expression via PI3K/AKT/p70S6K1 and HDM2/p53 pathways. FASEB J. 2005;19(3):342\u2013353.", "ArticleIdList": ["15746177"]}, {"Citation": "Mu R., Qi Q., Gu H. Involvement of p53 in oroxylin A-induced apoptosis in cancer cells. Mol Carcinog. 2009;48(12):1159\u20131169.", "ArticleIdList": ["19626645"]}, {"Citation": "Alonso M., Tamasdan C., Miller D.C. Flavopiridol induces apoptosis in glioma cell lines independent of retinoblastoma and p53 tumor suppressor pathway alterations by a caspase-independent pathway. Mol Cancer Ther. 2003;2(2):139\u2013150.", "ArticleIdList": ["12589031"]}, {"Citation": "Demidenko Z.N., Blagosklonny M.V. Flavopiridol induces p53 via initial inhibition of Mdm2 and p21 and, independently of p53, sensitizes apoptosis-reluctant cells to tumor necrosis factor. Cancer Res. 2004;64(10):3653\u20133660.", "ArticleIdList": ["15150125"]}, {"Citation": "Wang W., Wang H., Rayburn E.R. 20(S)-25-methoxyl-dammarane-3beta, 12beta, 20-triol, a novel natural product for prostate cancer therapy: activity in\u00a0vitro and in\u00a0vivo and mechanisms of action. Br J Cancer. 2008;98(4):792\u2013802.", "ArticleIdList": ["PMC2259179", "18253123"]}, {"Citation": "Wang W., Rayburn E.R., Zhao Y. Novel ginsenosides 25-OH-PPD and 25-OCH3-PPD as experimental therapy for pancreatic cancer: anticancer activity and mechanisms of action. Cancer Lett. 2009;278(2):241\u2013248.", "ArticleIdList": ["PMC2693424", "19203832"]}, {"Citation": "Wang W., Rayburn E.R., Hang J. Anti-lung cancer effects of novel ginsenoside 25-OCH(3)-PPD. Lung Cancer. 2009;65(3):306\u2013311.", "ArticleIdList": ["PMC2748063", "19131140"]}, {"Citation": "Wang W., Rayburn E.R., Hao M. Experimental therapy of prostate cancer with novel natural product anti-cancer ginsenosides. Prostate. 2008;68(8):809\u2013819.", "ArticleIdList": ["18324646"]}, {"Citation": "Wang W., Zhang X., Qin J.J. Natural product ginsenoside 25-OCH3-PPD inhibits breast cancer growth and metastasis through down-regulating MDM2. PLoS One. 2012;7(7):e41586.", "ArticleIdList": ["PMC3402429", "22911819"]}, {"Citation": "Zhang F., Li M., Wu X. 20(S)-ginsenoside Rg3 promotes senescence and apoptosis in gallbladder cancer cells via the p53 pathway. Drug Des Devel Ther. 2015;9:3969\u20133987.", "ArticleIdList": ["PMC4539091", "26309394"]}, {"Citation": "Liu X.H., Yao S., Levine A.C. Nandrolone, an anabolic steroid, stabilizes Numb protein through inhibition of mdm2 in C2C12 myoblasts. J Androl. 2012;33(6):1216\u20131223.", "ArticleIdList": ["22700758"]}, {"Citation": "Kong Y., Lu Z.L., Wang J.J. Platycodin D, a metabolite of Platycodin grandiflorum, inhibits highly metastatic MDA-MB-231 breast cancer growth in\u00a0vitro and in\u00a0vivo by targeting the MDM2 oncogene. Oncol Rep. 2016;36(3):1447\u20131456.", "ArticleIdList": ["27432230"]}, {"Citation": "Zhang X., Gu L., Li J. Degradation of MDM2 by the interaction between berberine and DAXX leads to potent apoptosis in MDM2-overexpressing cancer cells. Cancer Res. 2010;70(23):9895\u20139904.", "ArticleIdList": ["PMC2999659", "20935220"]}, {"Citation": "Liu J., Zhang X., Liu A. Berberine induces apoptosis in p53-null leukemia cells by down-regulating XIAP at the post-transcriptional level. Cell Physiol Biochem. 2013;32(5):1213\u20131224.", "ArticleIdList": ["24335171"]}, {"Citation": "Wang W., Nijampatnam B., Velu S.E. Discovery and development of synthetic tricyclic pyrroloquinone (TPQ) alkaloid analogs for human cancer therapy. Front Chem Sci Eng. 2016;10(1):1\u201315."}, {"Citation": "Zhou N., Li J., Li T. Matrineinduced apoptosis in Hep3B cells via the inhibition of MDM2. Mol Med Rep. 2017;15(1):442\u2013450.", "ArticleIdList": ["27959389"]}, {"Citation": "Proietti S., Cucina A., Dobrowolny G. Melatonin down-regulates MDM2 gene expression and enhances p53 acetylation in MCF-7 cells. J Pineal Res. 2014;57(1):120\u2013129.", "ArticleIdList": ["24920214"]}, {"Citation": "Rong J.J., Hu R., Qi Q. Gambogic acid down-regulates MDM2 oncogene and induces p21(Waf1/CIP1) expression independent of p53. Cancer Lett. 2009;284(1):102\u2013112.", "ArticleIdList": ["19428175"]}, {"Citation": "Tian L., Yin D., Ren Y. Plumbagin induces apoptosis via the p53 pathway and generation of reactive oxygen species in human osteosarcoma cells. Mol Med Rep. 2012;5(1):126\u2013132.", "ArticleIdList": ["21993662"]}, {"Citation": "Xiong J., Li J., Yang Q. Gossypol has anti-cancer effects by dual-targeting MDM2 and VEGF in human breast cancer. Breast Cancer Res. 2017;19(1):27.", "ArticleIdList": ["PMC5343402", "28274247"]}, {"Citation": "Huang M., Zhang H., Liu T. Triptolide inhibits MDM2 and induces apoptosis in acute lymphoblastic leukemia cells through a p53-independent pathway. Mol Cancer Ther. 2013;12(2):184\u2013194.", "ArticleIdList": ["PMC3570632", "23243057"]}, {"Citation": "Wang B.Y., Cao J., Chen J.W. Triptolide induces apoptosis of gastric cancer cells via inhibiting the overexpression of MDM2. Med Oncol. 2014;31(11):270.", "ArticleIdList": ["25280518"]}, {"Citation": "Gopal Y.N., Chanchorn E., Van Dyke M.W. Parthenolide promotes the ubiquitination of MDM2 and activates p53 cellular functions. Mol Cancer Ther. 2009;8(3):552\u2013562.", "ArticleIdList": ["19276167"]}, {"Citation": "Qin J.J., Wang W., Voruganti S. Identification of a new class of natural product MDM2 inhibitor: In\u00a0vitro and in\u00a0vivo anti-breast cancer activities and target validation. Oncotarget. 2015;6(5):2623\u20132640.", "ArticleIdList": ["PMC4413606", "25739118"]}, {"Citation": "Qin J.J., Wang W., Voruganti S. Inhibiting NFAT1 for breast cancer therapy: new insights into the mechanism of action of MDM2 inhibitor JapA. Oncotarget. 2015;6(32):33106\u201333119.", "ArticleIdList": ["PMC4741752", "26461225"]}, {"Citation": "Qin J.J., Wang W., Sarkar S. Inulanolide A as a new dual inhibitor of NFAT1-MDM2 pathway for breast cancer therapy. Oncotarget. 2016;7(22):32566\u201332578.", "ArticleIdList": ["PMC5078034", "27105525"]}, {"Citation": "Qin J.J., Li X., Wang W. Targeting the NFAT1-MDM2-MDMX network inhibits the proliferation and invasion of prostate cancer cells, independent of p53 and androgen. Front Pharmacol. 2017;8:917.", "ArticleIdList": ["PMC5735069", "29311926"]}, {"Citation": "Qin J.J., Sarkar S., Voruganti S. Identification of lineariifolianoid A as a novel dual NFAT1 and MDM2 inhibitor for human cancer therapy. J Biomed Res. 2016;30(4):322\u2013333.", "ArticleIdList": ["PMC4946323", "27533941"]}, {"Citation": "Li M., Zhang Z., Hill D.L. Curcumin, a dietary component, has anticancer, chemosensitization, and radiosensitization effects by down-regulating the MDM2 oncogene through the PI3K/mTOR/ETS2 pathway. Cancer Res. 2007;67(5):1988\u20131996.", "ArticleIdList": ["17332326"]}, {"Citation": "Tian Z., An N., Zhou B. Cytotoxic diarylheptanoid induces cell cycle arrest and apoptosis via increasing ATF3 and stabilizing p53 in SH-SY5Y cells. Cancer Chemother Pharmacol. 2009;63(6):1131\u20131139.", "ArticleIdList": ["PMC3709019", "18836721"]}, {"Citation": "Lu T.L., Huang G.J., Wang H.J. Hispolon promotes MDM2 downregulation through chaperone-mediated autophagy. Biochem Biophys Res Commun. 2010;398(1):26\u201331.", "ArticleIdList": ["20540933"]}, {"Citation": "Loch-Neckel G., Bicca M.A., Leal P.C. In\u00a0vitro and in\u00a0vivo anti-glioma activity of a chalcone-quinoxaline hybrid. Eur J Med Chem. 2015;90:93\u2013100.", "ArticleIdList": ["25461314"]}, {"Citation": "Stoll R., Renner C., Hansen S. Chalcone derivatives antagonize interactions between the human oncoprotein MDM2 and p53. Biochemistry. 2001;40(2):336\u2013344.", "ArticleIdList": ["11148027"]}, {"Citation": "Tsukamoto S., Yoshida T., Hosono H. Hexylitaconic acid: a new inhibitor of p53-HDM2 interaction isolated from a marine-derived fungus, Arthrinium sp. Bioorg Med Chem Lett. 2006;16(1):69\u201371.", "ArticleIdList": ["16246554"]}, {"Citation": "Duncan S.J., Gruschow S., Williams D.H. Isolation and structure elucidation of Chlorofusin, a novel p53-MDM2 antagonist from a Fusarium sp. J Am Chem Soc. 2001;123(4):554\u2013560.", "ArticleIdList": ["11456567"]}, {"Citation": "Malloy K.L., Choi H., Fiorilla C. Hoiamide D, a marine cyanobacteria-derived inhibitor of p53/MDM2 interaction. Bioorg Med Chem Lett. 2012;22(1):683\u2013688.", "ArticleIdList": ["PMC3248991", "22104152"]}, {"Citation": "Cominetti M.M., Goffin S.A., Raffel E. Identification of a new p53/MDM2 inhibitor motif inspired by studies of chlorofusin. Bioorg Med Chem Lett. 2015;25(21):4878\u20134880.", "ArticleIdList": ["26115576"]}, {"Citation": "Hsu Y.L., Uen Y.H., Chen Y. Tricetin, a dietary flavonoid, inhibits proliferation of human breast adenocarcinoma mcf-7 cells by blocking cell cycle progression and inducing apoptosis. J Agric Food Chem. 2009;57(18):8688\u20138695.", "ArticleIdList": ["19705844"]}, {"Citation": "Brew C.T., Aronchik I., Hsu J.C. Indole-3-carbinol activates the ATM signaling pathway independent of DNA damage to stabilize p53 and induce G1 arrest of human mammary epithelial cells. Int J Cancer. 2006;118(4):857\u2013868.", "ArticleIdList": ["16152627"]}, {"Citation": "Patil S.P., Pacitti M.F., Gilroy K.S. Identification of antipsychotic drug fluspirilene as a potential p53-MDM2 inhibitor: a combined computational and experimental study. J Comput Aided Mol Des. 2015;29(2):155\u2013163.", "ArticleIdList": ["25377899"]}, {"Citation": "Vogel S.M., Bauer M.R., Joerger A.C. Lithocholic acid is an endogenous inhibitor of MDM4 and MDM2. Proc Natl Acad Sci U S A. 2012;109(42):16906\u201316910.", "ArticleIdList": ["PMC3479485", "23035244"]}, {"Citation": "Chen C.Y., Hsu Y.L., Chen Y.Y. Isokotomolide A, a new butanolide extracted from the leaves of Cinnamomum kotoense, arrests cell cycle progression and induces apoptosis through the induction of p53/p21 and the initiation of mitochondrial system in human non-small cell lung cancer A549 cells. Eur J Pharmacol. 2007;574(2\u20133):94\u2013102.", "ArticleIdList": ["17707793"]}, {"Citation": "Menendez S., Higgins M., Berkson R.G. Nuclear export inhibitor leptomycin B induces the appearance of novel forms of human Mdm2 protein. Br J Cancer. 2003;88(4):636\u2013643.", "ArticleIdList": ["PMC2377168", "12592381"]}, {"Citation": "Wang W., Rayburn E.R., Velu S.E. In\u00a0vitro and in\u00a0vivo anticancer activity of novel synthetic makaluvamine analogues. Clin Cancer Res. 2009;15(10):3511\u20133518.", "ArticleIdList": ["PMC3769181", "19451594"]}, {"Citation": "Wang F., Ezell S.J., Zhang Y. FBA-TPQ, a novel marine-derived compound as experimental therapy for prostate cancer. Invest New Drugs. 2010;28(3):234\u2013241.", "ArticleIdList": ["PMC6690195", "19274441"]}, {"Citation": "Chen T., Xu Y., Guo H. Experimental therapy of ovarian cancer with synthetic makaluvamine analog: in\u00a0vitro and in\u00a0vivo anticancer activity and molecular mechanisms of action. PLoS One. 2011;6(6):e20729.", "ArticleIdList": ["PMC3108973", "21673964"]}, {"Citation": "Zhang X., Xu H., Zhang X. Preclinical evaluation of anticancer efficacy and pharmacological properties of FBA-TPQ, a novel synthetic makaluvamine analog. Mar Drugs. 2012;10(5):1138\u20131155.", "ArticleIdList": ["PMC3397457", "22822362"]}, {"Citation": "Wang W., Rayburn E.R., Velu S.E. A novel synthetic iminoquinone, BA-TPQ, as an anti-breast cancer agent: in\u00a0vitro and in\u00a0vivo activity and mechanisms of action. Breast Cancer Res Treat. 2010;123(2):321\u2013331.", "ArticleIdList": ["PMC3769174", "19936915"]}, {"Citation": "Nadkarni D.H., Wang F., Wang W. Synthesis and in\u00a0vitro anti-lung cancer activity of novel 1, 3, 4, 8-tetrahydropyrrolo [4, 3, 2-de]quinolin-8(1H)-one alkaloid analogs. Med Chem. 2009;5(3):227\u2013236.", "ArticleIdList": ["PMC6690190", "19442212"]}, {"Citation": "Sasiela C.A., Stewart D.H., Kitagaki J. Identification of inhibitors for MDM2 ubiquitin ligase activity from natural product extracts by a novel high-throughput electrochemiluminescent screen. J Biomol Screen. 2008;13(3):229\u2013237.", "ArticleIdList": ["18270365"]}, {"Citation": "Clement J.A., Kitagaki J., Yang Y. Discovery of new pyridoacridine alkaloids from Lissoclinum cf. badium that inhibit the ubiquitin ligase activity of Hdm2 and stabilize p53. Bioorg Med Chem. 2008;16(23):10022\u201310028.", "ArticleIdList": ["PMC2718708", "18977148"]}, {"Citation": "Kandoth C., McLellan M.D., Vandin F. Mutational landscape and significance across 12 major cancer types. Nature. 2013;502(7471):333\u2013339.", "ArticleIdList": ["PMC3927368", "24132290"]}, {"Citation": "Dong P., Tada M., Hamada J. p53 dominant-negative mutant R273H promotes invasion and migration of human endometrial cancer HHUA cells. Clin Exp Metastasis. 2007;24(6):471\u2013483.", "ArticleIdList": ["17636407"]}, {"Citation": "Mantovani F., Walerych D., Sal G.D. Targeting mutant p53 in cancer: a long road to precision therapy. FEBS J. 2017;284(6):837\u2013850.", "ArticleIdList": ["27808469"]}, {"Citation": "Bykov V.J.N., Eriksson S.E., Bianchi J. Targeting mutant p53 for efficient cancer therapy. Nat Rev Cancer. 2018;18(2):89\u2013102.", "ArticleIdList": ["29242642"]}, {"Citation": "Itabashi M., Segawa K., Ikeda Y. A new bioactive steroidal saponin, furcreastatin, from the plant Furcraea foetida. Carbohydr Res. 2000;323(1\u20134):57\u201362.", "ArticleIdList": ["10782286"]}, {"Citation": "Lu Y.P., Lou Y.R., Liao J. Administration of green tea or caffeine enhances the disappearance of UVB-induced patches of mutant p53 positive epidermal cells in SKH-1 mice. Carcinogenesis. 2005;26(8):1465\u20131472.", "ArticleIdList": ["15817611"]}, {"Citation": "Kramata P., Lu Y.P., Lou Y.R. Effect of administration of caffeine or green tea on the mutation profile in the p53 gene in early mutant p53-positive patches of epidermal cells induced by chronic UVB-irradiation of hairless SKH-1 mice. Carcinogenesis. 2005;26(11):1965\u20131974.", "ArticleIdList": ["15975959"]}, {"Citation": "Liu J., Jiang Z., Xiao J. Effects of triptolide from Tripterygium wilfordii on ERalpha and p53 expression in two human breast cancer cell lines. Phytomedicine. 2009;16(11):1006\u20131013.", "ArticleIdList": ["19524422"]}, {"Citation": "Karimi M., Conserva F., Mahmoudi S. Extract from Asteraceae Brachylaena ramiflora induces apoptosis preferentially in mutant p53-expressing human tumor cells. Carcinogenesis. 2010;31(6):1045\u20131053.", "ArticleIdList": ["20427345"]}, {"Citation": "Cho J.H., Lee J.G., Yang Y.I. Eupatilin, a dietary flavonoid, induces G2/M cell cycle arrest in human endometrial cancer cells. Food Chem Toxicol. 2011;49(8):1737\u20131744.", "ArticleIdList": ["21554918"]}, {"Citation": "Nian Y., Zhu H., Tang W.R. Triterpenes from the aerial parts of Cimicifuga yunnanensis and their antiproliferative effects on p53(N236S) mouse embryonic fibroblasts. J Nat Prod. 2013;76(5):896\u2013902.", "ArticleIdList": ["23621813"]}, {"Citation": "Al Dhaheri Y., Eid A., AbuQamar S. Mitotic arrest and apoptosis in breast cancer cells induced by Origanum majorana extract: upregulation of TNF-alpha and downregulation of survivin and mutant p53. PLoS One. 2013;8(2):e56649.", "ArticleIdList": ["PMC3579842", "23451065"]}, {"Citation": "Ding X., Zhu F., Yang Y. Purification, antitumor activity in\u00a0vitro of steroidal glycoalkaloids from black nightshade (Solanum nigrum L.) Food Chem. 2013;141(2):1181\u20131186.", "ArticleIdList": ["23790901"]}, {"Citation": "Wang L., Zeng Y., Liu Y. Fucoxanthin induces growth arrest and apoptosis in human bladder cancer T24 cells by up-regulation of p21 and down-regulation of mortalin. Acta Biochim Biophys Sin. 2014;46(10):877\u2013884.", "ArticleIdList": ["25187415"]}, {"Citation": "Thongrakard V., Titone R., Follo C. Turmeric toxicity in A431 epidermoid cancer cells associates with autophagy degradation of anti-apoptotic and anti-autophagic p53 mutant. Phytother Res. 2014;28(12):1761\u20131769.", "ArticleIdList": ["25044209"]}, {"Citation": "Hiraki M., Hwang S.Y., Cao S. Small-molecule reactivation of mutant p53 to wild-type-like p53 through the p53-Hsp40 regulatory axis. Chem Biol. 2015;22(9):1206\u20131216.", "ArticleIdList": ["PMC4670040", "26320861"]}, {"Citation": "Nayak S.K., Khatik G.L., Narang R. p53-Mdm2 interaction inhibitors as novel nongenotoxic anticancer agents. Curr Cancer Drug Targets. 2017 [Epub ahead of print]", "ArticleIdList": ["28669344"]}, {"Citation": "Wang S., Zhao Y., Aguilar A. Targeting the MDM2-p53 protein-protein interaction for new cancer therapy: progress and challenges. Cold Spring Harb Perspect Med. 2017;7(5)", "ArticleIdList": ["PMC5411684", "28270530"]}, {"Citation": "Tisato V., Voltan R., Gonelli A. MDM2/X inhibitors under clinical evaluation: perspectives for the management of hematological malignancies and pediatric cancer. J Hematol Oncol. 2017;10(1):133.", "ArticleIdList": ["PMC5496368", "28673313"]}]}], "History": [{"Year": "2018", "Month": "5", "Day": "13"}, {"Year": "2018", "Month": "7", "Day": "17"}, {"Year": "2018", "Month": "10", "Day": "16", "Hour": "6", "Minute": "0"}, {"Year": "2018", "Month": "10", "Day": "16", "Hour": "6", "Minute": "0"}, {"Year": "2018", "Month": "10", "Day": "16", "Hour": "6", "Minute": "1"}, {"Year": "2018", "Month": "7", "Day": "20"}], "PublicationStatus": "epublish", "ArticleIdList": ["30320185", "PMC6176154", "10.1016/j.gendis.2018.07.002", "S2352-3042(18)30075-8"]}}]}